Figure 9. BB6-PDT and tobramycin treatment of Pseudomonas aeruginosa wound-infected mice.

(A) Representative bioluminescence images of P. aeruginosa-infected mice (captured immediately post-infection, immediately post-treatment and 24 h post-treatment), receiving: no treatment (top row); treated with BB6, diagonal panel 24 h post-treatment shows two possible outcomes); and treated with a combination of BB6-PDT and 1 day Tobr (bottom row). (B) Quantification of luminescence values from bioluminescence images (not shown) obtained during the PDT process, or at equivalent times for non-PDT mice. *p < 0.05; **p < 0.01; ***p < 0.001; BB6 plus light (with and without Tobr) versus BB6 in dark and versus Tobr alone. (C) Kaplan–Meier survival curves for the groups of mice in Figure 9A; no treatment control (n = 10); PDT alone (n = 12); Tobr alone (n = 2); PDT plus Tobr (n = 10). PDT: Photodynamic therapy; Tobr: Tobramycin. Reprinted with permission from ⁴²